Careers  |  Sign In  |  Register

Latest in Oncology

Complementary Blood and Tissue Molecular Testing for Newly Diagnosed NSCLC

Dr. Socinski on Recommendations for Molecular Testing in Lung Cancer

Mark A. Socinski, MD, executive medical director at AdventHealth Cancer Institute, recommends immediate comprehensive molecular testing at the time of lung cancer diagnosis. Stating that oncogenic driver mutation identification is essential to effective targeted therapies, Dr. Socinski suggests complementary...
Erin M. Bertino, MD, medical oncologist at Ohio State University Comprehensive Cancer Center - James, provides a comparison of newly approved drug dacomitinib versus the other available FDA-approved EGFR tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Compared to gefitinib, dacomitinib had...
Jessica Bauman, MD, assistant professor of hematology/oncology at Fox Chase Cancer Center, discusses recent advancements in non-small cell lung cancer (NSCLC) treatment using targeted RET-fusion mutation therapies. RET-fusion driver mutations are sometimes seen in NSCLC, particularly in patients with...